RESEARCH TRIANGLE PARK, N.C. (
, the biotherapeutics company, has reached an agreement to be acquired by
, a Spanish health care company, for cash and stock of $3.4 billion.
Grifols, a leading producer of plasma protein therapies, said Monday the deal would create "a global leader of lifesaving and life-enhancing plasma protein therapeutics."
Grifols will acquire all the common shares of Talecris for $19 in cash and 0.641 newly issued non-voting Grifols shares for each Talecris share. The deal values Talecris shares at $26.16, a premium of 53% to the average closing price of Talecris common stock over the last 30 days.
Talecris shares closed Friday at $15.91.
The total value of the acquisition, including net debt, is about $4 billion.
The combined company will have pro forma annual revenue of about $2.8 billion with 58% coming from North America, 28% from Europe and 14% from the rest of the world, the companies said in a press release Monday.
-- Reported by Joseph Woelfel in New York.
Follow TheStreet.com on
and become a fan on
Copyright 2010 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.